News & Events

Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage biopharmaceutical company developing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors.

Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development.

We’re excited about our mission and are committed to sharing updates on our progress.

 

Press Releases

Featured
Immune-Onc Therapeutics Selected for Oral Presentation at American Society of Hematology (ASH) Annual Meeting to Showcase New Data from Phase 1b Study of IO-202 in Chronic Myelomonocytic Leukemia

Immune-Onc Therapeutics to Present Additional Positive Interim Data From IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress 

Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress 

Immune-Onc Therapeutics to Present Additional Positive Interim Data From IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress 

Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress

Immune-Onc Announces IO-202 CMML Interim Data at EHA2024

Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by USFDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic MyelomonocyticLeukemia (CMML)

Phase 1 study of IO-202 in combination with azacitidine currently enrolling newly diagnosed CMML patients

Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer

Collaboration to evaluate IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) as a potential first-line therapy for hepatocellular carcinoma

Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023
Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023
Immune-Onc Therapeutics Announces IO-108 Phase I Clinical Trial Results Selected for Oral Presentation at AACR Annual Meeting 2023
 

News & Events

Featured
Here are some recent breakthroughs by women-led life sciences companies in the Bay Area
Here are some recent breakthroughs by women-led life sciences companies in the Bay Area

Ari Mahrer, data reporter for the San Francisco Business Times, took a look at some of the monumental achievements from companies on their women-led life sciences list. Immune-Onc’s recent milestone: received Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia from the FDA.

IO-202 Receives FDA Orphan Drug Designation for CMML
IO-202 Receives FDA Orphan Drug Designation for CMML

The FDA has granted IO-202 an orphan drug designation for patients with chronic myelomonocytic leukemia.

LLS TAP: Pushing Boundaries and Transforming Lives for Patients with Rare Blood Cancers
LLS TAP: Pushing Boundaries and Transforming Lives for Patients with Rare Blood Cancers

One-hour live moderated discussion with The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) portfolio partners.

Dr Courtney DiNardo Sheds Light on FDA Fast Track Designation and Its Impact on Drug Development
Dr Courtney DiNardo Sheds Light on FDA Fast Track Designation and Its Impact on Drug Development

Courtney DiNardo, MD, MSCE, the lead author on a study presented at EHA 2023 evaluating a new therapy for chronic myelomonocytic leukemia and acute myeloid leukemia, discusses the FDA Fast Track Designation for IO-202 and strategies for raising awareness and improving diversity in clinical trials.

Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid Tumors
Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid Tumors

Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.

MedicalResearch.com Interview with Matthew H. Taylor, M.D., Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR
MedicalResearch.com Interview with Matthew H. Taylor, M.D., Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR

AACR 2023: Phase 1 Trial of IO-108, An Antagonist Antibody Targeting LILRB2 (ILT4), as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors

IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors
IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors

Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.

Here are six major breakthroughs achieved by Bay Area women-led biotechs
Here are six major breakthroughs achieved by Bay Area women-led biotechs

Advances in drug discovery and development were the clear standouts for Bay Area women-led life sciences companies.

 

Media Contact

Tara Cooper
The Grace Communication Group
tara@gracegroup.us